2. Cell Cycle/DNA Damage Cytoskeleton Apoptosis Metabolic Enzyme/Protease
  3. Microtubule/Tubulin Apoptosis Endogenous Metabolite
  4. Docetaxel

Docétaxel (RP-56976) est un agent antinéoplasique et inhibe la dépolymérisation des microtubules avec une valeur IC50 de 0,2 μM. Docétaxel (RP-56976) atténue les effets de l'expression des gènes bcl-2 et bcl-xL. Docétaxel (RP-56976) arrête le cycle cellulaire à G2/M et conduit à l'apoptose cellulaire.

Docetaxel (RP-56976) ist ein antineoplastisches Mittel und hemmt die microtubule depolymerization mit einem IC50-Wert von 0,2 μM. Docetaxel (RP-56976) schwächt die Auswirkungen der bcl-2 and bcl-xL-Genexpression ab. Docetaxel (RP-56976) hemmt den Zellzyklus bei G2/M und führt zur apoptosis.

Docetaxel (RP-56976) is a microtubule depolymerization inhibitor, with an IC50 of 0.2 μM. Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity.

For research use only. We do not sell to patients.

CAS No. : 114977-28-5

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
100 mg In-stock
200 mg In-stock
1 g In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 158 publication(s) in Google Scholar

Other Forms of Docetaxel:

Docetaxel Related Antibodies

Top Publications Citing Use of Products

158 Publications Citing Use of MCE Docetaxel

Apoptosis Analysis
WB
Cell Proliferation/Viability Assay

    Docetaxel purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Nov 20:e2407662.  [Abstract]

    Representative images and quantitative analysis of surviving clones after treatment of C4-2B and LNCaP cells with PBS or ECM1 protein (200 ng/mL) in the presence of docetaxel (10 μM) were shown.

    Docetaxel purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Nov 20:e2407662.  [Abstract]

    Flow cytometry analysis showed representative images and quantification of apoptosis in C4-2B and LNCaP cells in the presence of docetaxel (10 μM). Docetaxel caused PCa cell apoptosis compared to that in the vehicle group.

    Docetaxel purchased from MedChemExpress. Usage Cited in: Sci Transl Med. 2024 Apr 3;16(741):eadj5705.  [Abstract]

    Growth inhibition by docetaxel (Doc) (0–10 μM) in TS− or TS+ CAFs isolated from patients with BC was observed. The survival rates of TSPAN8+ CAFs were enhanced compared with TSPAN8− CAFs when challenged with an equal dosage of docetaxel.

    Docetaxel purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2023 May 3;16(1):46.  [Abstract]

    Under docetaxel treatment (0.5 nM, 1 nM, 2.5 nM, 5 nM, 10 nM, 20 nM, 48 hours), myeloid-like tumor hybrid cells were less sensitive than the RM1 cell line.

    Docetaxel purchased from MedChemExpress. Usage Cited in: Arch Biochem Biophys. 2023 Mar 15:737:109551.  [Abstract]

    Docetaxel (30 nM) exhibits anti-tumor activity in parental (DU145 and PC-3) and docetaxel-resistant (DU145/DTX50 and PC-3/DTX30) cell lines by down-regulating KIF14 expression.

    Docetaxel purchased from MedChemExpress. Usage Cited in: Oncotarget. 2016 May 17;7(20):28891-902.  [Abstract]

    Western blot analyses for Brachyury and AR expression in prostate cell lines treated with Docetaxel (Doc) or with XRP6258 (Cab). Graphs represent the densimetric semi-quantification of western blot images.

    View All Endogenous Metabolite Isoform Specific Products:

    View All Isoforms
    Human Endogenous Metabolite Microbial Metabolite

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Docetaxel (RP-56976) is a microtubule depolymerization inhibitor, with an IC50 of 0.2 μM. Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity[1][3].

    IC50 & Target

    Microtubule[1]
    Cellular Effect
    Cell Line Type Value Description References
    1A9 IC50
    3.55 1
    Compound: 8
    Cytotoxicity against human 1A9 cells
    Cytotoxicity against human 1A9 cells
    		[PMID: 28850227]
    DU-145 IC50
    0.1 1
    Compound: Docetaxel
    Antiproliferative activity against human DU145 cells
    Antiproliferative activity against human DU145 cells
    		[PMID: 31251599]
    A2780 IC50
    11.2 1
    Compound: 1b
    Cytotoxicity against human A2780 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A2780 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 29359935]
    DU-145 IC50
    0.1 1
    Compound: Docetaxel
    Cytotoxicity against human DU145 cells after 72 hrs by MTS assay
    Cytotoxicity against human DU145 cells after 72 hrs by MTS assay
    		[PMID: 29406710]
    A549 IC50
    19.5 1
    Compound: Docetaxel
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    		[PMID: 34058663]
    KB GI50
    0.13 1
    Compound: Docetaxel
    Growth inhibition of human KB cells after 72 hrs by MTS assay
    Growth inhibition of human KB cells after 72 hrs by MTS assay
    		[PMID: 26778612]
    A549 IC50
    3.41 3
    Compound: DTX
    Cytotoxicity against human A-549 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    Cytotoxicity against human A-549 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    		[PMID: 26791014]
    LNCaP IC50
    0.2 1
    Compound: Docetaxel
    Antiproliferative activity against androgen-insensitive human LNCaP cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    Antiproliferative activity against androgen-insensitive human LNCaP cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    		[PMID: 33753258]
    A549 IC50
    734 1
    Compound: Docetaxel
    Cytotoxicity against human paclitaxl resistant A549 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human paclitaxl resistant A549 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30036834]
    LNCaP IC50
    0.2 1
    Compound: Docetaxel
    Antiproliferative activity against docetaxel-sensitive human LNCAP cells after 3 days by WST-1 assay
    Antiproliferative activity against docetaxel-sensitive human LNCAP cells after 3 days by WST-1 assay
    		[PMID: 29784275]
    A549 IC50
    9.8 1
    Compound: Docetaxel
    Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30036834]
    A549/TR IC50
    836.2 1
    Compound: Docetaxel
    Cytotoxicity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    Cytotoxicity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    		[PMID: 34058663]
    A549 IC50
    3.41 3
    Compound: DTX
    Cytotoxicity against human A-549 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    Cytotoxicity against human A-549 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    		[PMID: 26791014]
    HeLa IC50
    0.3 1
    Compound: Docetaxel
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 30629433]
    Calu-1 IC50
    0.4 1
    Compound: Docetaxel
    Antiproliferative activity against human Calu1 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Calu1 cells after 72 hrs by MTT assay
    		[PMID: 30629433]
    Calu-1 IC50
    0.4 1
    Compound: Docetaxel
    Antiproliferative activity against human Calu1 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Calu1 cells after 72 hrs by MTT assay
    		[PMID: 30629433]
    CAPAN-1 IC50
    0.0088 3
    Compound: Docetaxel
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    MCF7 IC50
    0.5 1
    Compound: Docetaxel
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 30629433]
    CAPAN-1 IC50
    0.025 3
    Compound: Docetaxel
    Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    CCD-18Co IC50
    116.54 3
    Compound: DTX
    Cytotoxicity against human CCD-18Co cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human CCD-18Co cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 32203786]
    MV4-11 GI50
    0.5 1
    Compound: Taxotere
    Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    		[PMID: 30802730]
    CWR22R CC50
    1 1
    Compound: Docetaxel
    Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 34717125]
    PC-3 IC50
    0.5 1
    Compound: Docetaxel
    Antiproliferative activity against human PC3 cells
    Antiproliferative activity against human PC3 cells
    		[PMID: 31251599]
    CWR22R CC50
    3.3 1
    Compound: Docetaxel
    Cytotoxicity against human 22Rv1 cells expressing PMSA measured using MTT assay
    Cytotoxicity against human 22Rv1 cells expressing PMSA measured using MTT assay
    		[PMID: 34797052]
    PC-3 IC50
    0.5 1
    Compound: Docetaxel
    Cytotoxicity against human PC3 cells after 72 hrs by MTS assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTS assay
    		[PMID: 29406710]
    PC-3 IC50
    0.6 1
    Compound: Docetaxel
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 30629433]
    CWR22R GI50
    6 14
    Compound: Dxtl
    Growth inhibition of human 22Rv1 cells incubated for 48 hrs by MTS assay
    Growth inhibition of human 22Rv1 cells incubated for 48 hrs by MTS assay
    		[PMID: 31767266]
    DU-145 IC50
    0.0012 3
    Compound: Docetaxel
    Antiproliferative activity against androgen-insensitive human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    Antiproliferative activity against androgen-insensitive human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    		[PMID: 33753258]
    PC-3 IC50
    0.6 1
    Compound: Docetaxel
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    		[PMID: 36126331]
    DU-145 IC50
    0.0012 3
    Compound: Docetaxel
    Antiproliferative activity against docetaxel-sensitive human DU145 cells after 3 days by WST-1 assay
    Antiproliferative activity against docetaxel-sensitive human DU145 cells after 3 days by WST-1 assay
    		[PMID: 29784275]
    HeLa IC50
    0.7 1
    Compound: Docetaxel
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 38294341]
    DU-145 IC50
    0.01 3
    Compound: Docetaxel
    Antiproliferative activity in human DU145 cells by sulforhodamine B assay
    Antiproliferative activity in human DU145 cells by sulforhodamine B assay
    		[PMID: 29120172]
    U-251 IC50
    0.7 1
    Compound: Docetaxel
    Antiproliferative activity against human U251MG cells after 72 hrs by MTT assay
    Antiproliferative activity against human U251MG cells after 72 hrs by MTT assay
    		[PMID: 30629433]
    SK-OV-3 IC50
    0.75 1
    Compound: Taxotere
    Cytotoxicity against human SKOV3 cells after 72 to 120 hrs by sulforhodamine B assay
    Cytotoxicity against human SKOV3 cells after 72 to 120 hrs by sulforhodamine B assay
    		[PMID: 29517223]
    DU-145 IC50
    0.026 3
    Compound: Docetaxel
    Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    		[PMID: 27077446]
    A-375 IC50
    4.5 1
    Compound: DT
    Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    		[PMID: 38959729]
    CWR22R CC50
    1 1
    Compound: Docetaxel
    Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 34717125]
    DU-145 IC50
    0.1 1
    Compound: Docetaxel
    Cytotoxicity against human DU145 cells after 72 hrs by MTS assay
    Cytotoxicity against human DU145 cells after 72 hrs by MTS assay
    		[PMID: 29406710]
    A-427 GI50
    4.4 1
    Compound: Docetaxel
    Growth inhibition of human A-427 cells measured after 72 to 96 hrs by cell-titer glo assay
    Growth inhibition of human A-427 cells measured after 72 to 96 hrs by cell-titer glo assay
    		[PMID: 39102508]
    DU-145 CC50
    0.81 3
    Compound: Docetaxel
    Cytotoxic activity in human DU145 cells by sulforhodamine B assay
    Cytotoxic activity in human DU145 cells by sulforhodamine B assay
    		[PMID: 29120172]
    CAPAN-1 IC50
    0.019 3
    Compound: Docetaxel
    Antiproliferative activity against human Capan1 cells
    Antiproliferative activity against human Capan1 cells
    		[PMID: 31005446]
    CAPAN-1 IC50
    0.0088 3
    Compound: Docetaxel
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    DU-145 IC50
    4.95 1
    Compound: Docetaxel
    Cytotoxicity against human DU-145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU-145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31945665]
    CAPAN-1 IC50
    0.025 3
    Compound: Docetaxel
    Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    A2780 IC50
    11.2 1
    Compound: 1b
    Cytotoxicity against human A2780 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A2780 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 29359935]
    DU-145 IC50
    43.25 1
    Compound: Docetaxel
    Cytotoxicity against human DU-145 cells over expressing CYP1B1 assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU-145 cells over expressing CYP1B1 assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31945665]
    A2780 IC50
    2.9 1
    Compound: 1b
    Antiproliferative activity against human A2780 cells assessed as inhibition of cell viability by MTT assay
    Antiproliferative activity against human A2780 cells assessed as inhibition of cell viability by MTT assay
    		[PMID: 37490800]
    LNCaP IC50
    1 1
    Compound: DTX
    Cytotoxicity against human LNCaP cells assessed as reduction in cell viability
    Cytotoxicity against human LNCaP cells assessed as reduction in cell viability
    		[PMID: 34464875]
    DU-145 IC50
    5 6
    Compound: Docetaxel
    Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth by MTT assay
    Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 34000484]
    A2780 IC50
    3 1
    Compound: Docetaxel
    Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 38294341]
    CAPAN-1 IC50
    0.95 3
    Compound: Docetaxel
    Cytostatic activity against human Capan1 cells
    Cytostatic activity against human Capan1 cells
    		[PMID: 30738653]
    DU-145 IC50
    8.58 3
    Compound: Docetaxel
    Antiproliferative activity against Docetaxel-resistant human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    Antiproliferative activity against Docetaxel-resistant human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    		[PMID: 33753258]
    CCD-18Co IC50
    116.54 3
    Compound: DTX
    Cytotoxicity against human CCD-18Co cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human CCD-18Co cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 32203786]
    HCT-116 IC50
    0.0017 3
    Compound: Docetaxel
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    HCT-116 IC50
    0.007 3
    Compound: Docetaxel
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    PC-3 CC50
    1 1
    Compound: Docetaxel
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 34717125]
    HCT-116 IC50
    129.8 1
    Compound: Docetaxel
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 28972762]
    MCF7 IC50
    1.7 1
    Compound: Docetaxel
    Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30036834]
    A549 IC50
    18 1
    Compound: Docetaxel
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 38294341]
    HCT-116 IC50
    3.5 1
    Compound: DTX
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32203786]
    CWR22R IC50
    2.1 1
    Compound: DTX
    Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability
    Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability
    		[PMID: 34464875]
    A549 IC50
    19.5 1
    Compound: Docetaxel
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    		[PMID: 34058663]
    HCT-116 IC50
    4 1
    Compound: Docetaxel
    Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 33221063]
    T84 IC50
    2.7 1
    Compound: Docetaxel
    Anticancer activity against human T84 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Anticancer activity against human T84 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 33221063]
    A549 IC50
    3.41 3
    Compound: DTX
    Cytotoxicity against human A-549 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    Cytotoxicity against human A-549 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    		[PMID: 26791014]
    HEK293 IC50
    0.11 3
    Compound: Docetaxel
    Antiproliferative activity in HEK293 cells by sulforhodamine B assay
    Antiproliferative activity in HEK293 cells by sulforhodamine B assay
    		[PMID: 29120172]
    A2780 IC50
    3 1
    Compound: Docetaxel
    Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 38294341]
    CWR22R CC50
    3.3 1
    Compound: Docetaxel
    Cytotoxicity against human 22Rv1 cells expressing PMSA measured using MTT assay
    Cytotoxicity against human 22Rv1 cells expressing PMSA measured using MTT assay
    		[PMID: 34797052]
    HEK293 CC50
    1.6 3
    Compound: Docetaxel
    Cytotoxic activity in HEK293 cells by sulforhodamine B assay
    Cytotoxic activity in HEK293 cells by sulforhodamine B assay
    		[PMID: 29120172]
    A549 IC50
    734 1
    Compound: Docetaxel
    Cytotoxicity against human paclitaxl resistant A549 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human paclitaxl resistant A549 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30036834]
    HEK293 IC50
    19.7 3
    Compound: DTX
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32203786]
    A549 IC50
    9.8 1
    Compound: Docetaxel
    Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30036834]
    HeLa IC50
    3.5 1
    Compound: 1b
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 29359935]
    HeLa IC50
    0.061 3
    Compound: Docetaxel
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by MTT assay
    		[PMID: 27077446]
    1A9 IC50
    3.55 1
    Compound: 8
    Cytotoxicity against human 1A9 cells
    Cytotoxicity against human 1A9 cells
    		[PMID: 28850227]
    HCT-116 IC50
    4 1
    Compound: Docetaxel
    Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 33221063]
    HeLa IC50
    0.07 3
    Compound: Docetaxel
    Antiproliferative activity in human HeLa cells by sulforhodamine B assay
    Antiproliferative activity in human HeLa cells by sulforhodamine B assay
    		[PMID: 29120172]
    A549/TR IC50
    836.2 1
    Compound: Docetaxel
    Cytotoxicity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    Cytotoxicity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    		[PMID: 34058663]
    HeLa CC50
    0.09 3
    Compound: Docetaxel
    Cytotoxic activity in human HeLa cells by sulforhodamine B assay
    Cytotoxic activity in human HeLa cells by sulforhodamine B assay
    		[PMID: 29120172]
    CWR22R GI50
    6 14
    Compound: Dxtl
    Growth inhibition of human 22Rv1 cells incubated for 48 hrs by MTS assay
    Growth inhibition of human 22Rv1 cells incubated for 48 hrs by MTS assay
    		[PMID: 31767266]
    BT-474 IC50
    21.4 1
    Compound: DT
    Antiproliferative activity against human BT-474 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    Antiproliferative activity against human BT-474 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    		[PMID: 38959729]
    SW-620 IC50
    4.7 1
    Compound: Docetaxel
    Anticancer activity against human SW-620 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Anticancer activity against human SW-620 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 33221063]
    HeLa IC50
    0.3 1
    Compound: Docetaxel
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 30629433]
    DU-145 CC50
    0.81 3
    Compound: Docetaxel
    Cytotoxic activity in human DU145 cells by sulforhodamine B assay
    Cytotoxic activity in human DU145 cells by sulforhodamine B assay
    		[PMID: 29120172]
    CAKI-1 IC50
    2.7 1
    Compound: DT
    Antiproliferative activity against human CAKI-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    Antiproliferative activity against human CAKI-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    		[PMID: 38959729]
    HeLa IC50
    0.68 3
    Compound: Docetaxel
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    		[PMID: 36126331]
    HeLa IC50
    13 3
    Compound: Docetaxel
    Growth inhibition of human HeLa cells over expressing beta3-tubulin measured after 96 hrs by sulforhodamine B assay
    Growth inhibition of human HeLa cells over expressing beta3-tubulin measured after 96 hrs by sulforhodamine B assay
    		[PMID: 27894589]
    DU-145 IC50
    0.0012 3
    Compound: Docetaxel
    Antiproliferative activity against androgen-insensitive human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    Antiproliferative activity against androgen-insensitive human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    		[PMID: 33753258]
    CAPAN-1 IC50
    0.0088 3
    Compound: Docetaxel
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    DU-145 IC50
    8.58 3
    Compound: Docetaxel
    Antiproliferative activity against Docetaxel-resistant human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    Antiproliferative activity against Docetaxel-resistant human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    		[PMID: 33753258]
    HeLa IC50
    3.23 3
    Compound: DTX
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    		[PMID: 26791014]
    CAPAN-1 IC50
    0.019 3
    Compound: Docetaxel
    Antiproliferative activity against human Capan1 cells
    Antiproliferative activity against human Capan1 cells
    		[PMID: 31005446]
    DU-145 IC50
    0.0012 3
    Compound: Docetaxel
    Antiproliferative activity against docetaxel-sensitive human DU145 cells after 3 days by WST-1 assay
    Antiproliferative activity against docetaxel-sensitive human DU145 cells after 3 days by WST-1 assay
    		[PMID: 29784275]
    HeLa IC50
    3.5 1
    Compound: 1b
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 29359935]
    HeLa IC50
    4 3
    Compound: Docetaxel
    Growth inhibition of human HeLa cells measured after 96 hrs by sulforhodamine B assay
    Growth inhibition of human HeLa cells measured after 96 hrs by sulforhodamine B assay
    		[PMID: 27894589]
    CAPAN-1 IC50
    0.025 3
    Compound: Docetaxel
    Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    DU-145 IC50
    4.95 1
    Compound: Docetaxel
    Cytotoxicity against human DU-145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU-145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31945665]
    CAPAN-1 IC50
    0.95 3
    Compound: Docetaxel
    Cytostatic activity against human Capan1 cells
    Cytostatic activity against human Capan1 cells
    		[PMID: 30738653]
    HEp-2 CC50
    0.06 3
    Compound: Docetaxel
    Cytotoxic activity in human Hep2 cells by sulforhodamine B assay
    Cytotoxic activity in human Hep2 cells by sulforhodamine B assay
    		[PMID: 29120172]
    DU-145 IC50
    0.01 3
    Compound: Docetaxel
    Antiproliferative activity in human DU145 cells by sulforhodamine B assay
    Antiproliferative activity in human DU145 cells by sulforhodamine B assay
    		[PMID: 29120172]
    DU-145 IC50
    0.026 3
    Compound: Docetaxel
    Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    		[PMID: 27077446]
    CCD-18Co IC50
    116.54 3
    Compound: DTX
    Cytotoxicity against human CCD-18Co cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human CCD-18Co cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 32203786]
    HEp-2 IC50
    0.06 3
    Compound: Docetaxel
    Antiproliferative activity in human Hep2 cells by sulforhodamine B assay
    Antiproliferative activity in human Hep2 cells by sulforhodamine B assay
    		[PMID: 29120172]
    DU-145 IC50
    5 6
    Compound: Docetaxel
    Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth by MTT assay
    Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 34000484]
    HepG2 IC50
    2.86 3
    Compound: DTX
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    		[PMID: 26791014]
    CWR22R CC50
    1 1
    Compound: Docetaxel
    Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 34717125]
    HepG2 IC50
    8.3 3
    Compound: Docetaxel
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 27617953]
    DU-145 IC50
    5 1
    Compound: Docetaxel
    Cytotoxicity against human DU-145 cells
    Cytotoxicity against human DU-145 cells
    		[PMID: 33951490]
    CWR22R CC50
    3.3 1
    Compound: Docetaxel
    Cytotoxicity against human 22Rv1 cells expressing PMSA measured using MTT assay
    Cytotoxicity against human 22Rv1 cells expressing PMSA measured using MTT assay
    		[PMID: 34797052]
    HEY IC50
    0.86 3
    Compound: Taxotere
    Cytotoxicity against human HEY cells after 72 to 120 hrs by sulforhodamine B assay
    Cytotoxicity against human HEY cells after 72 to 120 hrs by sulforhodamine B assay
    		[PMID: 29517223]
    PC-3 IC50
    5 1
    Compound: Docetaxel
    Cytotoxicity against human PC3 cells
    Cytotoxicity against human PC3 cells
    		[PMID: 28462831]
    CWR22R GI50
    6 14
    Compound: Dxtl
    Growth inhibition of human 22Rv1 cells incubated for 48 hrs by MTS assay
    Growth inhibition of human 22Rv1 cells incubated for 48 hrs by MTS assay
    		[PMID: 31767266]
    HL-60 IC50
    0.0072 3
    Compound: Docetaxel
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    HCT-116 IC50
    0.004 3
    Compound: Docetaxel
    Antiproliferative activity against human HCT116 cells
    Antiproliferative activity against human HCT116 cells
    		[PMID: 31005446]
    CWR22R IC50
    2.1 1
    Compound: DTX
    Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability
    Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability
    		[PMID: 34464875]
    HL-60 IC50
    0.05 3
    Compound: Docetaxel
    Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    DU-145 EC50
    6.05 1
    Compound: Docetaxel
    Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 37290495]
    K562 IC50
    0.009 3
    Compound: Docetaxel
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    HCT-116 IC50
    0.0017 3
    Compound: Docetaxel
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    K562 IC50
    0.0152 3
    Compound: Docetaxel
    Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    HCT-116 IC50
    0.007 3
    Compound: Docetaxel
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    HCT-116 IC50
    3.5 × 10-3 3
    Compound: DTX
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32203786]
    K562 IC50
    0.039 3
    Compound: Docetaxel
    Cytotoxicity against human K562 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    		[PMID: 27077446]
    PC-3 CC50
    6.7 1
    Compound: Docetaxel
    Cytotoxicity against human PC-3 cells not expressing PMSA measured using MTT assay
    Cytotoxicity against human PC-3 cells not expressing PMSA measured using MTT assay
    		[PMID: 34797052]
    KB IC50
    0.05 3
    Compound: Docetaxel
    Antiproliferative activity in human KB cells by sulforhodamine B assay
    Antiproliferative activity in human KB cells by sulforhodamine B assay
    		[PMID: 29120172]
    KB GI50
    0.13 1
    Compound: Docetaxel
    Growth inhibition of human KB cells after 72 hrs by MTS assay
    Growth inhibition of human KB cells after 72 hrs by MTS assay
    		[PMID: 26778612]
    HEK293 CC50
    1.6 3
    Compound: Docetaxel
    Cytotoxic activity in HEK293 cells by sulforhodamine B assay
    Cytotoxic activity in HEK293 cells by sulforhodamine B assay
    		[PMID: 29120172]
    Calu-1 IC50
    0.4 1
    Compound: Docetaxel
    Antiproliferative activity against human Calu1 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Calu1 cells after 72 hrs by MTT assay
    		[PMID: 30629433]
    KB CC50
    0.18 3
    Compound: Docetaxel
    Cytotoxic activity in human KB cells by sulforhodamine B assay
    Cytotoxic activity in human KB cells by sulforhodamine B assay
    		[PMID: 29120172]
    KB IC50
    7.3 1
    Compound: Docetaxel
    Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30036834]
    PC-3 EC50
    7.6 1
    Compound: Docetaxel
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 37290495]
    KB IC50
    17.5 1
    Compound: Docetaxel
    Cytotoxicity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    Cytotoxicity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    		[PMID: 34058663]
    PC-3 IC50
    8 1
    Compound: Docetaxel
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by trypan blue exclusion assay
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by trypan blue exclusion assay
    		[PMID: 28462831]
    KB IC50
    38 1
    Compound: Docetaxel
    Cytotoxicity against human KB cells by MTT assay
    Cytotoxicity against human KB cells by MTT assay
    		[PMID: 30407813]
    A549 IC50
    9.8 1
    Compound: Docetaxel
    Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30036834]
    DU-145 CC50
    0.81 3
    Compound: Docetaxel
    Cytotoxic activity in human DU145 cells by sulforhodamine B assay
    Cytotoxic activity in human DU145 cells by sulforhodamine B assay
    		[PMID: 29120172]
    KB IC50
    7.3 1
    Compound: Docetaxel
    Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30036834]
    HEK293 IC50
    0.11 3
    Compound: Docetaxel
    Antiproliferative activity in HEK293 cells by sulforhodamine B assay
    Antiproliferative activity in HEK293 cells by sulforhodamine B assay
    		[PMID: 29120172]
    DU-145 EC50
    6.05 1
    Compound: Docetaxel
    Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 37290495]
    L132 IC50
    1.68 3
    Compound: DTX
    Cytotoxicity against human L-132 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    Cytotoxicity against human L-132 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    		[PMID: 26791014]
    DU-145 IC50
    0.0012 3
    Compound: Docetaxel
    Antiproliferative activity against docetaxel-sensitive human DU145 cells after 3 days by WST-1 assay
    Antiproliferative activity against docetaxel-sensitive human DU145 cells after 3 days by WST-1 assay
    		[PMID: 29784275]
    LN-229 IC50
    0.002 3
    Compound: Docetaxel
    Antiproliferative activity against human LN229 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human LN229 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    HEK293 IC50
    19.7 3
    Compound: DTX
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32203786]
    MCF7 IC50
    10.3 1
    Compound: Docetaxel
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 30407813]
    LNCaP IC50
    0.0002 3
    Compound: Docetaxel
    Antiproliferative activity against androgen-insensitive human LNCaP cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    Antiproliferative activity against androgen-insensitive human LNCaP cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    		[PMID: 33753258]
    DU-145 IC50
    0.0012 3
    Compound: Docetaxel
    Antiproliferative activity against androgen-insensitive human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    Antiproliferative activity against androgen-insensitive human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    		[PMID: 33753258]
    DU-145 IC50
    0.01 3
    Compound: Docetaxel
    Antiproliferative activity in human DU145 cells by sulforhodamine B assay
    Antiproliferative activity in human DU145 cells by sulforhodamine B assay
    		[PMID: 29120172]
    LNCaP IC50
    0.0002 3
    Compound: Docetaxel
    Antiproliferative activity against docetaxel-sensitive human LNCAP cells after 3 days by WST-1 assay
    Antiproliferative activity against docetaxel-sensitive human LNCAP cells after 3 days by WST-1 assay
    		[PMID: 29784275]
    A2780 IC50
    11.2 1
    Compound: 1b
    Cytotoxicity against human A2780 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A2780 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 29359935]
    HeLa IC50
    13 1
    Compound: Docetaxel
    Antiproliferative activity against human HeLa cells expressing tubulin betaIII assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells expressing tubulin betaIII assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 38294341]
    DU-145 IC50
    0.026 3
    Compound: Docetaxel
    Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    		[PMID: 27077446]
    MCF7 CC50
    0.01 3
    Compound: Docetaxel
    Cytotoxic activity in human MCF7 cells by sulforhodamine B assay
    Cytotoxic activity in human MCF7 cells by sulforhodamine B assay
    		[PMID: 29120172]
    HeLa CC50
    0.09 3
    Compound: Docetaxel
    Cytotoxic activity in human HeLa cells by sulforhodamine B assay
    Cytotoxic activity in human HeLa cells by sulforhodamine B assay
    		[PMID: 29120172]
    DU-145 IC50
    0.04 3
    Compound: PC
    Cytotoxicity against human DU-145 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human DU-145 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 39102454]
    MCF7 IC50
    0.01 3
    Compound: Docetaxel
    Antiproliferative activity in human MCF7 cells by sulforhodamine B assay
    Antiproliferative activity in human MCF7 cells by sulforhodamine B assay
    		[PMID: 29120172]
    DU-145 IC50
    0.1 1
    Compound: Docetaxel
    Cytotoxicity against human DU145 cells after 72 hrs by MTS assay
    Cytotoxicity against human DU145 cells after 72 hrs by MTS assay
    		[PMID: 29406710]
    MCF7 IC50
    0.022 3
    Compound: Docetaxel
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    		[PMID: 27077446]
    HeLa IC50
    0.07 3
    Compound: Docetaxel
    Antiproliferative activity in human HeLa cells by sulforhodamine B assay
    Antiproliferative activity in human HeLa cells by sulforhodamine B assay
    		[PMID: 29120172]
    DU-145 IC50
    0.1 1
    Compound: Docetaxel
    Antiproliferative activity against human DU145 cells
    Antiproliferative activity against human DU145 cells
    		[PMID: 31251599]
    MCF7 IC50
    0.5 1
    Compound: Docetaxel
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 30629433]
    HeLa IC50
    0.061 3
    Compound: Docetaxel
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by MTT assay
    		[PMID: 27077446]
    DU-145 IC50
    4.95 1
    Compound: Docetaxel
    Cytotoxicity against human DU-145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU-145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31945665]
    MCF7 IC50
    0.8 3
    Compound: Docetaxel
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    		[PMID: 27240278]
    HeLa IC50
    0.68 3
    Compound: Docetaxel
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    		[PMID: 36126331]
    DU-145 IC50
    43.25 1
    Compound: Docetaxel
    Cytotoxicity against human DU-145 cells over expressing CYP1B1 assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU-145 cells over expressing CYP1B1 assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31945665]
    MCF7 IC50
    1.7 1
    Compound: Docetaxel
    Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30036834]
    HeLa IC50
    3.23 3
    Compound: DTX
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    		[PMID: 26791014]
    DU-145 IC50
    5 1
    Compound: Docetaxel
    Cytotoxicity against human DU-145 cells
    Cytotoxicity against human DU-145 cells
    		[PMID: 33951490]
    HeLa IC50
    4 3
    Compound: Docetaxel
    Growth inhibition of human HeLa cells measured after 96 hrs by sulforhodamine B assay
    Growth inhibition of human HeLa cells measured after 96 hrs by sulforhodamine B assay
    		[PMID: 27894589]
    MCF7 IC50
    10.3 1
    Compound: Docetaxel
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 30407813]
    DU-145 IC50
    5.4 3
    Compound: Docetaxel
    Cytotoxicity against human DU-145 cells assessed as cell death measured by MTT assay
    Cytotoxicity against human DU-145 cells assessed as cell death measured by MTT assay
    		[PMID: 39137365]
    HeLa IC50
    13 3
    Compound: Docetaxel
    Growth inhibition of human HeLa cells over expressing beta3-tubulin measured after 96 hrs by sulforhodamine B assay
    Growth inhibition of human HeLa cells over expressing beta3-tubulin measured after 96 hrs by sulforhodamine B assay
    		[PMID: 27894589]
    MCF7 IC50
    3.6 3
    Compound: DTX
    Cytotoxicity against human MCF-7 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    Cytotoxicity against human MCF-7 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    		[PMID: 26791014]
    KB IC50
    17.5 1
    Compound: Docetaxel
    Cytotoxicity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    Cytotoxicity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    		[PMID: 34058663]
    MDA-MB-231 IC50
    0.01 3
    Compound: Docetaxel
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    		[PMID: 33139111]
    DU-145 IC50
    5 6
    Compound: Docetaxel
    Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth by MTT assay
    Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 34000484]
    DU-145 IC50
    8.58 3
    Compound: Docetaxel
    Antiproliferative activity against Docetaxel-resistant human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    Antiproliferative activity against Docetaxel-resistant human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    		[PMID: 33753258]
    MDA-MB-231 IC50
    0.032 3
    Compound: Docetaxel
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    		[PMID: 27077446]
    HEp-2 CC50
    0.06 3
    Compound: Docetaxel
    Cytotoxic activity in human Hep2 cells by sulforhodamine B assay
    Cytotoxic activity in human Hep2 cells by sulforhodamine B assay
    		[PMID: 29120172]
    MDA-MB-231 IC50
    0.07 3
    Compound: Docetaxel
    Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay
    Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay
    		[PMID: 29120172]
    HEp-2 IC50
    0.06 3
    Compound: Docetaxel
    Antiproliferative activity in human Hep2 cells by sulforhodamine B assay
    Antiproliferative activity in human Hep2 cells by sulforhodamine B assay
    		[PMID: 29120172]
    MDA-MB-231 CC50
    0.19 3
    Compound: Docetaxel
    Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay
    Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay
    		[PMID: 29120172]
    A549 IC50
    18 1
    Compound: Docetaxel
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 38294341]
    MM1.S IC50
    0.0118 3
    Compound: Docetaxel
    Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    HepG2 IC50
    2.86 3
    Compound: DTX
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    		[PMID: 26791014]
    MV4-11 GI50
    0.0005 3
    Compound: Taxotere
    Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    		[PMID: 30802730]
    A549 IC50
    19.5 1
    Compound: Docetaxel
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    		[PMID: 34058663]
    NCI/ADR-RES IC50
    1530.5 1
    Compound: Docetaxel
    Cytotoxicity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30036834]
    HepG2 IC50
    8.3 3
    Compound: Docetaxel
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 27617953]
    HCT-116 IC50
    0.0017 3
    Compound: Docetaxel
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    NCI/ADR-RES IC50
    21.2 3
    Compound: Docetaxel
    Cytotoxicity against human MCF7/ADR cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    Cytotoxicity against human MCF7/ADR cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    		[PMID: 27240278]
    HEY IC50
    0.86 3
    Compound: Taxotere
    Cytotoxicity against human HEY cells after 72 to 120 hrs by sulforhodamine B assay
    Cytotoxicity against human HEY cells after 72 to 120 hrs by sulforhodamine B assay
    		[PMID: 29517223]
    HCT-116 IC50
    0.004 3
    Compound: Docetaxel
    Antiproliferative activity against human HCT116 cells
    Antiproliferative activity against human HCT116 cells
    		[PMID: 31005446]
    NCI-H460 IC50
    0.0024 3
    Compound: Docetaxel
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    HL-60 IC50
    0.047 3
    Compound: Docetaxel
    Antiproliferative activity against human HL60 cells
    Antiproliferative activity against human HL60 cells
    		[PMID: 31005446]
    HL-60 IC50
    0.0072 3
    Compound: Docetaxel
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    HCT-116 IC50
    0.007 3
    Compound: Docetaxel
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    NCI-H460 IC50
    0.004 3
    Compound: Docetaxel
    Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    HCT-116 IC50
    129.8 1
    Compound: Docetaxel
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 28972762]
    PC-3 IC50
    0.0006 3
    Compound: Docetaxel
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    		[PMID: 36126331]
    HL-60 IC50
    0.05 3
    Compound: Docetaxel
    Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    HCT-116 IC50
    3.5 x 10-3 3
    Compound: DTX
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32203786]
    PC-3 IC50
    0.0019 3
    Compound: Docetaxel
    Antiproliferative activity against androgen-insensitive human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    Antiproliferative activity against androgen-insensitive human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    		[PMID: 33753258]
    HL-60 IC50
    1.94 3
    Compound: Docetaxel
    Cytostatic activity against human HL60 cells
    Cytostatic activity against human HL60 cells
    		[PMID: 30738653]
    HCT-116 IC50
    4 1
    Compound: Docetaxel
    Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 33221063]
    PC-3 IC50
    0.0019 3
    Compound: Docetaxel
    Antiproliferative activity against docetaxel-sensitive human PC3 cells after 3 days by WST-1 assay
    Antiproliferative activity against docetaxel-sensitive human PC3 cells after 3 days by WST-1 assay
    		[PMID: 29784275]
    K562 IC50
    0.016 3
    Compound: Docetaxel
    Antiproliferative activity against human K562 cells
    Antiproliferative activity against human K562 cells
    		[PMID: 31005446]
    K562 IC50
    0.0152 3
    Compound: Docetaxel
    Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    PC-3 IC50
    0.013 3
    Compound: Docetaxel
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    		[PMID: 27077446]
    PC-3 IC50
    0.5 1
    Compound: Docetaxel
    Cytotoxicity against human PC3 cells after 72 hrs by MTS assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTS assay
    		[PMID: 29406710]
    K562 IC50
    0.009 3
    Compound: Docetaxel
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    HEK293 CC50
    1.6 3
    Compound: Docetaxel
    Cytotoxic activity in HEK293 cells by sulforhodamine B assay
    Cytotoxic activity in HEK293 cells by sulforhodamine B assay
    		[PMID: 29120172]
    PC-3 IC50
    0.6 1
    Compound: Docetaxel
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 30629433]
    K562 IC50
    3 3
    Compound: Docetaxel
    Cytostatic activity against human K562 cells
    Cytostatic activity against human K562 cells
    		[PMID: 30738653]
    HEK293 IC50
    0.11 3
    Compound: Docetaxel
    Antiproliferative activity in HEK293 cells by sulforhodamine B assay
    Antiproliferative activity in HEK293 cells by sulforhodamine B assay
    		[PMID: 29120172]
    PC-3 CC50
    1 1
    Compound: Docetaxel
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 34717125]
    K562 IC50
    0.039 3
    Compound: Docetaxel
    Cytotoxicity against human K562 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    		[PMID: 27077446]
    HEK293 IC50
    19.7 3
    Compound: DTX
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32203786]
    KB CC50
    0.18 3
    Compound: Docetaxel
    Cytotoxic activity in human KB cells by sulforhodamine B assay
    Cytotoxic activity in human KB cells by sulforhodamine B assay
    		[PMID: 29120172]
    PC-3 IC50
    2.34 3
    Compound: Docetaxel
    Antiproliferative activity against Docetaxel-resistant human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    Antiproliferative activity against Docetaxel-resistant human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    		[PMID: 33753258]
    HEK293 IC50
    7.5 1
    Compound: DT
    Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    		[PMID: 38959729]
    PC-3 CC50
    6.7 1
    Compound: Docetaxel
    Cytotoxicity against human PC-3 cells not expressing PMSA measured using MTT assay
    Cytotoxicity against human PC-3 cells not expressing PMSA measured using MTT assay
    		[PMID: 34797052]
    KB IC50
    38 1
    Compound: Docetaxel
    Cytotoxicity against human KB cells by MTT assay
    Cytotoxicity against human KB cells by MTT assay
    		[PMID: 30407813]
    HEY IC50
    0.86 3
    Compound: Taxotere
    Cytotoxicity against human HEY cells after 72 to 120 hrs by sulforhodamine B assay
    Cytotoxicity against human HEY cells after 72 to 120 hrs by sulforhodamine B assay
    		[PMID: 29517223]
    KB IC50
    0.05 3
    Compound: Docetaxel
    Antiproliferative activity in human KB cells by sulforhodamine B assay
    Antiproliferative activity in human KB cells by sulforhodamine B assay
    		[PMID: 29120172]
    PC-3 IC50
    8 1
    Compound: Docetaxel
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by trypan blue exclusion assay
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by trypan blue exclusion assay
    		[PMID: 28462831]
    HEp-2 CC50
    0.06 3
    Compound: Docetaxel
    Cytotoxic activity in human Hep2 cells by sulforhodamine B assay
    Cytotoxic activity in human Hep2 cells by sulforhodamine B assay
    		[PMID: 29120172]
    PC-3 GI50
    9 14
    Compound: Dxtl
    Growth inhibition of human PC3 cells incubated for 48 hrs by MTS assay
    Growth inhibition of human PC3 cells incubated for 48 hrs by MTS assay
    		[PMID: 31767266]
    DU-145 IC50
    43.25 1
    Compound: Docetaxel
    Cytotoxicity against human DU-145 cells over expressing CYP1B1 assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU-145 cells over expressing CYP1B1 assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31945665]
    HEp-2 IC50
    0.06 3
    Compound: Docetaxel
    Antiproliferative activity in human Hep2 cells by sulforhodamine B assay
    Antiproliferative activity in human Hep2 cells by sulforhodamine B assay
    		[PMID: 29120172]
    RWPE-1 IC50
    1.73 3
    Compound: Docetaxel
    Cytotoxicity against human RWPE1 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human RWPE1 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    		[PMID: 27077446]
    L132 IC50
    1.68 3
    Compound: DTX
    Cytotoxicity against human L-132 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    Cytotoxicity against human L-132 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    		[PMID: 26791014]
    LN-229 IC50
    0.002 3
    Compound: Docetaxel
    Antiproliferative activity against human LN229 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human LN229 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    SH-SY5Y IC50
    0.0018 3
    Compound: Docetaxel
    Cytotoxicity against human SH-SY5Y cells assessed as inhibition of cell growth and measured upto 72 hrs by clonogenic assay
    Cytotoxicity against human SH-SY5Y cells assessed as inhibition of cell growth and measured upto 72 hrs by clonogenic assay
    		[PMID: 36126331]
    HL-60 IC50
    0.0072 3
    Compound: Docetaxel
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    HL-60 IC50
    0.047 3
    Compound: Docetaxel
    Antiproliferative activity against human HL60 cells
    Antiproliferative activity against human HL60 cells
    		[PMID: 31005446]
    SiHa IC50
    0.09 3
    Compound: Docetaxel
    Antiproliferative activity in human SiHa cells by sulforhodamine B assay
    Antiproliferative activity in human SiHa cells by sulforhodamine B assay
    		[PMID: 29120172]
    MCF7 CC50
    0.01 3
    Compound: Docetaxel
    Cytotoxic activity in human MCF7 cells by sulforhodamine B assay
    Cytotoxic activity in human MCF7 cells by sulforhodamine B assay
    		[PMID: 29120172]
    HL-60 IC50
    0.05 3
    Compound: Docetaxel
    Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    SiHa CC50
    0.22 3
    Compound: Docetaxel
    Cytotoxic activity in human SiHa cells by sulforhodamine B assay
    Cytotoxic activity in human SiHa cells by sulforhodamine B assay
    		[PMID: 29120172]
    MCF7 IC50
    0.01 3
    Compound: Docetaxel
    Antiproliferative activity in human MCF7 cells by sulforhodamine B assay
    Antiproliferative activity in human MCF7 cells by sulforhodamine B assay
    		[PMID: 29120172]
    HL-60 IC50
    1.94 3
    Compound: Docetaxel
    Cytostatic activity against human HL60 cells
    Cytostatic activity against human HL60 cells
    		[PMID: 30738653]
    MCF7 IC50
    0.022 3
    Compound: Docetaxel
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    		[PMID: 27077446]
    SK-MEL19 GI50
    0.002 3
    Compound: Taxotere
    Antiproliferative activity against human SK-MEL-19 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    Antiproliferative activity against human SK-MEL-19 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    		[PMID: 30802730]
    HT-1080 IC50
    1.5 1
    Compound: DT
    Antiproliferative activity against human HT-1080 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    Antiproliferative activity against human HT-1080 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    		[PMID: 38959729]
    MCF7 IC50
    0.8 3
    Compound: Docetaxel
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    		[PMID: 27240278]
    SK-OV-3 IC50
    0.75 1
    Compound: Taxotere
    Cytotoxicity against human SKOV3 cells after 72 to 120 hrs by sulforhodamine B assay
    Cytotoxicity against human SKOV3 cells after 72 to 120 hrs by sulforhodamine B assay
    		[PMID: 29517223]
    HeLa CC50
    0.09 3
    Compound: Docetaxel
    Cytotoxic activity in human HeLa cells by sulforhodamine B assay
    Cytotoxic activity in human HeLa cells by sulforhodamine B assay
    		[PMID: 29120172]
    MCF7 IC50
    3.6 3
    Compound: DTX
    Cytotoxicity against human MCF-7 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    Cytotoxicity against human MCF-7 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    		[PMID: 26791014]
    SW-620 IC50
    0.02 3
    Compound: DTX
    Cytotoxicity against human SW-620 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human SW-620 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 32203786]
    HeLa IC50
    0.061 3
    Compound: Docetaxel
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by MTT assay
    		[PMID: 27077446]
    SW-620 IC50
    4.7 1
    Compound: Docetaxel
    Anticancer activity against human SW-620 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Anticancer activity against human SW-620 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 33221063]
    MDA-MB-231 CC50
    0.19 3
    Compound: Docetaxel
    Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay
    Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay
    		[PMID: 29120172]
    MDA-MB-231 IC50
    4.68 3
    Compound: Docetaxel
    Antiproliferative activity against docetaxel-resistant human MDA-MB-231-DTR cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against docetaxel-resistant human MDA-MB-231-DTR cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 36786551]
    HeLa IC50
    0.07 3
    Compound: Docetaxel
    Antiproliferative activity in human HeLa cells by sulforhodamine B assay
    Antiproliferative activity in human HeLa cells by sulforhodamine B assay
    		[PMID: 29120172]
    T84 IC50
    2.7 1
    Compound: Docetaxel
    Anticancer activity against human T84 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Anticancer activity against human T84 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 33221063]
    MDA-MB-231 IC50
    1.98 3
    Compound: Docetaxel
    Antiproliferative activity against docetaxel-resistant human MDA-MB-231-DTR cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay
    Antiproliferative activity against docetaxel-resistant human MDA-MB-231-DTR cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay
    		[PMID: 36786551]
    HeLa IC50
    0.3 1
    Compound: Docetaxel
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 30629433]
    TERT-RPE1 IC50
    0.0553 3
    Compound: Docetaxel
    Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by real time imaging analysis
    Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by real time imaging analysis
    		[PMID: 33248847]
    HeLa IC50
    0.68 3
    Compound: Docetaxel
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    		[PMID: 36126331]
    U-251 IC50
    0.7 1
    Compound: Docetaxel
    Antiproliferative activity against human U251MG cells after 72 hrs by MTT assay
    Antiproliferative activity against human U251MG cells after 72 hrs by MTT assay
    		[PMID: 30629433]
    MDA-MB-231 IC50
    0.01 3
    Compound: Docetaxel
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    		[PMID: 33139111]
    HeLa IC50
    0.7 1
    Compound: 1b
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability by MTT assay
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability by MTT assay
    		[PMID: 37490800]
    Vero IC50
    0.13 3
    Compound: Docetaxel
    Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay
    Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay
    		[PMID: 29120172]
    MDA-MB-231 IC50
    0.02 3
    Compound: Docetaxel
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 36786551]
    HeLa IC50
    0.7 1
    Compound: Docetaxel
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 38294341]
    Vero CC50
    1.3 3
    Compound: Docetaxel
    Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay
    Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay
    		[PMID: 29120172]
    MDA-MB-231 IC50
    0.07 3
    Compound: Docetaxel
    Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay
    Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay
    		[PMID: 29120172]
    Z-138 IC50
    0.004 3
    Compound: Docetaxel
    Antiproliferative activity against human Z138 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human Z138 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    MDA-MB-231 IC50
    0.032 3
    Compound: Docetaxel
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    		[PMID: 27077446]
    HeLa IC50
    1 1
    Compound: DT
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    		[PMID: 38959729]
    HeLa IC50
    13 1
    Compound: 1b
    Antiproliferative activity against human HeLa cells overexpressing betaIII-tubulin assessed as inhibition of cell viability by MTT assay
    Antiproliferative activity against human HeLa cells overexpressing betaIII-tubulin assessed as inhibition of cell viability by MTT assay
    		[PMID: 37490800]
    MM1.S IC50
    0.0118 3
    Compound: Docetaxel
    Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    Z-138 IC50
    0.0142 3
    Compound: Docetaxel
    Antiproliferative activity against human Z138 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human Z138 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    HeLa IC50
    13 1
    Compound: Docetaxel
    Antiproliferative activity against human HeLa cells expressing tubulin betaIII assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells expressing tubulin betaIII assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 38294341]
    HCT-116 IC50
    129.8 1
    Compound: Docetaxel
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 28972762]
    HeLa IC50
    13 3
    Compound: Docetaxel
    Growth inhibition of human HeLa cells over expressing beta3-tubulin measured after 96 hrs by sulforhodamine B assay
    Growth inhibition of human HeLa cells over expressing beta3-tubulin measured after 96 hrs by sulforhodamine B assay
    		[PMID: 27894589]
    NCI/ADR-RES IC50
    21.2 3
    Compound: Docetaxel
    Cytotoxicity against human MCF7/ADR cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    Cytotoxicity against human MCF7/ADR cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    		[PMID: 27240278]
    NCI-H460 IC50
    0.007 3
    Compound: Docetaxel
    Antiproliferative activity against human NCI-H460 cells
    Antiproliferative activity against human NCI-H460 cells
    		[PMID: 31005446]
    HeLa IC50
    3.23 3
    Compound: DTX
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    		[PMID: 26791014]
    HeLa IC50
    3.5 1
    Compound: 1b
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 29359935]
    NCI-H460 IC50
    0.0024 3
    Compound: Docetaxel
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    HeLa IC50
    4 3
    Compound: Docetaxel
    Growth inhibition of human HeLa cells measured after 96 hrs by sulforhodamine B assay
    Growth inhibition of human HeLa cells measured after 96 hrs by sulforhodamine B assay
    		[PMID: 27894589]
    NCI-H460 IC50
    0.004 3
    Compound: Docetaxel
    Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    NCI-H460 IC50
    0.89 3
    Compound: Docetaxel
    Cytostatic activity against human NCI-H460 cells
    Cytostatic activity against human NCI-H460 cells
    		[PMID: 30738653]
    HepG2 IC50
    2.86 3
    Compound: DTX
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    		[PMID: 26791014]
    HepG2 IC50
    8.3 3
    Compound: Docetaxel
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 27617953]
    PC-3 GI50
    9 14
    Compound: Dxtl
    Growth inhibition of human PC3 cells incubated for 48 hrs by MTS assay
    Growth inhibition of human PC3 cells incubated for 48 hrs by MTS assay
    		[PMID: 31767266]
    K562 IC50
    0.009 3
    Compound: Docetaxel
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    PC-3 IC50
    0.0019 3
    Compound: Docetaxel
    Antiproliferative activity against androgen-insensitive human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    Antiproliferative activity against androgen-insensitive human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    		[PMID: 33753258]
    K562 IC50
    0.0152 3
    Compound: Docetaxel
    Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    PC-3 IC50
    2.34 3
    Compound: Docetaxel
    Antiproliferative activity against Docetaxel-resistant human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    Antiproliferative activity against Docetaxel-resistant human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    		[PMID: 33753258]
    K562 IC50
    0.016 3
    Compound: Docetaxel
    Antiproliferative activity against human K562 cells
    Antiproliferative activity against human K562 cells
    		[PMID: 31005446]
    PC-3 IC50
    0.0019 3
    Compound: Docetaxel
    Antiproliferative activity against docetaxel-sensitive human PC3 cells after 3 days by WST-1 assay
    Antiproliferative activity against docetaxel-sensitive human PC3 cells after 3 days by WST-1 assay
    		[PMID: 29784275]
    K562 IC50
    0.039 3
    Compound: Docetaxel
    Cytotoxicity against human K562 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    		[PMID: 27077446]
    PC-3 IC50
    0.013 3
    Compound: Docetaxel
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    		[PMID: 27077446]
    PC-6 GI50
    1.48 14
    Compound: 162
    Growth inhibition of human PC-6 cells
    Growth inhibition of human PC-6 cells
    		[PMID: 34213340]
    K562 IC50
    3 3
    Compound: Docetaxel
    Cytostatic activity against human K562 cells
    Cytostatic activity against human K562 cells
    		[PMID: 30738653]
    KB CC50
    0.18 3
    Compound: Docetaxel
    Cytotoxic activity in human KB cells by sulforhodamine B assay
    Cytotoxic activity in human KB cells by sulforhodamine B assay
    		[PMID: 29120172]
    A549 IC50
    734 1
    Compound: Docetaxel
    Cytotoxicity against human paclitaxl resistant A549 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human paclitaxl resistant A549 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30036834]
    KB GI50
    0.13 1
    Compound: Docetaxel
    Growth inhibition of human KB cells after 72 hrs by MTS assay
    Growth inhibition of human KB cells after 72 hrs by MTS assay
    		[PMID: 26778612]
    RWPE-1 IC50
    1.73 3
    Compound: Docetaxel
    Cytotoxicity against human RWPE1 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human RWPE1 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    		[PMID: 27077446]
    KB IC50
    0.05 3
    Compound: Docetaxel
    Antiproliferative activity in human KB cells by sulforhodamine B assay
    Antiproliferative activity in human KB cells by sulforhodamine B assay
    		[PMID: 29120172]
    A549/TR IC50
    836.2 1
    Compound: Docetaxel
    Cytotoxicity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    Cytotoxicity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    		[PMID: 34058663]
    NCI/ADR-RES IC50
    1530.5 1
    Compound: Docetaxel
    Cytotoxicity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30036834]
    KB IC50
    17.5 1
    Compound: Docetaxel
    Cytotoxicity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    Cytotoxicity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    		[PMID: 34058663]
    KB IC50
    38 1
    Compound: Docetaxel
    Cytotoxicity against human KB cells by MTT assay
    Cytotoxicity against human KB cells by MTT assay
    		[PMID: 30407813]
    SH-SY5Y IC50
    0.0018 3
    Compound: Docetaxel
    Cytotoxicity against human SH-SY5Y cells assessed as inhibition of cell growth and measured upto 72 hrs by clonogenic assay
    Cytotoxicity against human SH-SY5Y cells assessed as inhibition of cell growth and measured upto 72 hrs by clonogenic assay
    		[PMID: 36126331]
    KB IC50
    7.3 1
    Compound: Docetaxel
    Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30036834]
    SiHa CC50
    0.22 3
    Compound: Docetaxel
    Cytotoxic activity in human SiHa cells by sulforhodamine B assay
    Cytotoxic activity in human SiHa cells by sulforhodamine B assay
    		[PMID: 29120172]
    L132 IC50
    1.68 3
    Compound: DTX
    Cytotoxicity against human L-132 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    Cytotoxicity against human L-132 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    		[PMID: 26791014]
    SiHa IC50
    0.09 3
    Compound: Docetaxel
    Antiproliferative activity in human SiHa cells by sulforhodamine B assay
    Antiproliferative activity in human SiHa cells by sulforhodamine B assay
    		[PMID: 29120172]
    LN-229 IC50
    0.002 3
    Compound: Docetaxel
    Antiproliferative activity against human LN229 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human LN229 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    SK-MEL19 GI50
    0.002 3
    Compound: Taxotere
    Antiproliferative activity against human SK-MEL-19 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    Antiproliferative activity against human SK-MEL-19 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    		[PMID: 30802730]
    LNCaP IC50
    0.0002 3
    Compound: Docetaxel
    Antiproliferative activity against docetaxel-sensitive human LNCAP cells after 3 days by WST-1 assay
    Antiproliferative activity against docetaxel-sensitive human LNCAP cells after 3 days by WST-1 assay
    		[PMID: 29784275]
    SW-620 IC50
    0.02 3
    Compound: DTX
    Cytotoxicity against human SW-620 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human SW-620 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 32203786]
    LNCaP IC50
    0.0002 3
    Compound: Docetaxel
    Antiproliferative activity against androgen-insensitive human LNCaP cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    Antiproliferative activity against androgen-insensitive human LNCaP cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    		[PMID: 33753258]
    TERT-RPE1 IC50
    25 3
    Compound: Docetaxel
    Cytostatic activity against human hTERT-RPE1 cells
    Cytostatic activity against human hTERT-RPE1 cells
    		[PMID: 30738653]
    LNCaP IC50
    1 1
    Compound: DTX
    Cytotoxicity against human LNCaP cells assessed as reduction in cell viability
    Cytotoxicity against human LNCaP cells assessed as reduction in cell viability
    		[PMID: 34464875]
    TERT-RPE1 IC50
    0.0553 3
    Compound: Docetaxel
    Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by real time imaging analysis
    Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by real time imaging analysis
    		[PMID: 33248847]
    LNCaP IC50
    12.3 3
    Compound: Docetaxel
    Cytotoxicity against human LNCaP cells assessed as cell death measured by MTT assay
    Cytotoxicity against human LNCaP cells assessed as cell death measured by MTT assay
    		[PMID: 39137365]
    Vero CC50
    1.3 3
    Compound: Docetaxel
    Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay
    Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay
    		[PMID: 29120172]
    Vero IC50
    0.13 3
    Compound: Docetaxel
    Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay
    Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay
    		[PMID: 29120172]
    MCF7 CC50
    0.01 3
    Compound: Docetaxel
    Cytotoxic activity in human MCF7 cells by sulforhodamine B assay
    Cytotoxic activity in human MCF7 cells by sulforhodamine B assay
    		[PMID: 29120172]
    MCF7 IC50
    0.01 3
    Compound: Docetaxel
    Antiproliferative activity in human MCF7 cells by sulforhodamine B assay
    Antiproliferative activity in human MCF7 cells by sulforhodamine B assay
    		[PMID: 29120172]
    Z-138 IC50
    0.009 3
    Compound: Docetaxel
    Antiproliferative activity against human Z138 cells
    Antiproliferative activity against human Z138 cells
    		[PMID: 31005446]
    MCF7 IC50
    0.022 3
    Compound: Docetaxel
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    		[PMID: 27077446]
    Z-138 IC50
    0.0142 3
    Compound: Docetaxel
    Antiproliferative activity against human Z138 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human Z138 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    MCF7 IC50
    0.5 1
    Compound: Docetaxel
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 30629433]
    Z-138 IC50
    0.004 3
    Compound: Docetaxel
    Antiproliferative activity against human Z138 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human Z138 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    MCF7 IC50
    0.8 3
    Compound: Docetaxel
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    		[PMID: 27240278]
    Z-138 IC50
    3 3
    Compound: Docetaxel
    Cytostatic activity against human Z138 cells
    Cytostatic activity against human Z138 cells
    		[PMID: 30738653]
    MCF7 IC50
    1.7 1
    Compound: Docetaxel
    Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30036834]
    MCF7 IC50
    10.3 1
    Compound: Docetaxel
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 30407813]
    MCF7 IC50
    3.6 3
    Compound: DTX
    Cytotoxicity against human MCF-7 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    Cytotoxicity against human MCF-7 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    		[PMID: 26791014]
    MCF7 IC50
    3.9 1
    Compound: DT
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    		[PMID: 38959729]
    MDA-MB-231 CC50
    0.19 3
    Compound: Docetaxel
    Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay
    Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay
    		[PMID: 29120172]
    MDA-MB-231 IC50
    0.01 3
    Compound: Docetaxel
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    		[PMID: 33139111]
    MDA-MB-231 IC50
    0.02 3
    Compound: Docetaxel
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 36786551]
    MDA-MB-231 IC50
    0.032 3
    Compound: Docetaxel
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    		[PMID: 27077446]
    MDA-MB-231 IC50
    0.07 3
    Compound: Docetaxel
    Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay
    Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay
    		[PMID: 29120172]
    MDA-MB-231 IC50
    0.17 3
    Compound: PC
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 39102454]
    MDA-MB-231 IC50
    1.98 3
    Compound: Docetaxel
    Antiproliferative activity against docetaxel-resistant human MDA-MB-231-DTR cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay
    Antiproliferative activity against docetaxel-resistant human MDA-MB-231-DTR cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay
    		[PMID: 36786551]
    MDA-MB-231 IC50
    38.9 3
    Compound: Docetaxel
    Cytotoxicity against human MDA-MB-231 cells assessed as cell death measured by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell death measured by MTT assay
    		[PMID: 39137365]
    MDA-MB-231 IC50
    4.68 3
    Compound: Docetaxel
    Antiproliferative activity against docetaxel-resistant human MDA-MB-231-DTR cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against docetaxel-resistant human MDA-MB-231-DTR cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 36786551]
    MDA-MB-468 IC50
    3.1 1
    Compound: DT
    Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    		[PMID: 38959729]
    MES-SA IC50
    3.4 1
    Compound: DT
    Antiproliferative activity against human MES-SA cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    Antiproliferative activity against human MES-SA cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    		[PMID: 38959729]
    MM1.S IC50
    0.0118 3
    Compound: Docetaxel
    Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    MV4-11 GI50
    0.0005 3
    Compound: Taxotere
    Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    		[PMID: 30802730]
    NCI-H460 IC50
    0.0024 3
    Compound: Docetaxel
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    NCI-H460 IC50
    0.004 3
    Compound: Docetaxel
    Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    NCI-H460 IC50
    0.007 3
    Compound: Docetaxel
    Antiproliferative activity against human NCI-H460 cells
    Antiproliferative activity against human NCI-H460 cells
    		[PMID: 31005446]
    NCI-H460 IC50
    0.89 3
    Compound: Docetaxel
    Cytostatic activity against human NCI-H460 cells
    Cytostatic activity against human NCI-H460 cells
    		[PMID: 30738653]
    NCI/ADR-RES IC50
    1530.5 1
    Compound: Docetaxel
    Cytotoxicity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30036834]
    NCI/ADR-RES IC50
    21.2 3
    Compound: Docetaxel
    Cytotoxicity against human MCF7/ADR cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    Cytotoxicity against human MCF7/ADR cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    		[PMID: 27240278]
    PC-3 CC50
    1 1
    Compound: Docetaxel
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 34717125]
    PC-3 CC50
    6.7 1
    Compound: Docetaxel
    Cytotoxicity against human PC-3 cells not expressing PMSA measured using MTT assay
    Cytotoxicity against human PC-3 cells not expressing PMSA measured using MTT assay
    		[PMID: 34797052]
    PC-3 EC50
    7.6 1
    Compound: Docetaxel
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 37290495]
    PC-3 GI50
    9 14
    Compound: Dxtl
    Growth inhibition of human PC3 cells incubated for 48 hrs by MTS assay
    Growth inhibition of human PC3 cells incubated for 48 hrs by MTS assay
    		[PMID: 31767266]
    PC-3 IC50
    0.0006 3
    Compound: Docetaxel
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    		[PMID: 36126331]
    PC-3 IC50
    0.0019 3
    Compound: Docetaxel
    Antiproliferative activity against docetaxel-sensitive human PC3 cells after 3 days by WST-1 assay
    Antiproliferative activity against docetaxel-sensitive human PC3 cells after 3 days by WST-1 assay
    		[PMID: 29784275]
    PC-3 IC50
    0.0019 3
    Compound: Docetaxel
    Antiproliferative activity against androgen-insensitive human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    Antiproliferative activity against androgen-insensitive human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    		[PMID: 33753258]
    PC-3 IC50
    0.013 3
    Compound: Docetaxel
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    		[PMID: 27077446]
    PC-3 IC50
    0.5 1
    Compound: Docetaxel
    Cytotoxicity against human PC3 cells after 72 hrs by MTS assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTS assay
    		[PMID: 29406710]
    PC-3 IC50
    0.5 1
    Compound: Docetaxel
    Antiproliferative activity against human PC3 cells
    Antiproliferative activity against human PC3 cells
    		[PMID: 31251599]
    PC-3 IC50
    0.6 1
    Compound: Docetaxel
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 30629433]
    PC-3 IC50
    12.5 3
    Compound: Docetaxel
    Cytotoxicity against human PC-3 cells assessed as cell death measured by MTT assay
    Cytotoxicity against human PC-3 cells assessed as cell death measured by MTT assay
    		[PMID: 39137365]
    PC-3 IC50
    2.34 3
    Compound: Docetaxel
    Antiproliferative activity against Docetaxel-resistant human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    Antiproliferative activity against Docetaxel-resistant human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    		[PMID: 33753258]
    PC-3 IC50
    5 1
    Compound: Docetaxel
    Cytotoxicity against human PC3 cells
    Cytotoxicity against human PC3 cells
    		[PMID: 28462831]
    PC-3 IC50
    8 1
    Compound: Docetaxel
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by trypan blue exclusion assay
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by trypan blue exclusion assay
    		[PMID: 28462831]
    PC-6 GI50
    1.48 14
    Compound: 162
    Growth inhibition of human PC-6 cells
    Growth inhibition of human PC-6 cells
    		[PMID: 34213340]
    RWPE-1 IC50
    1.73 3
    Compound: Docetaxel
    Cytotoxicity against human RWPE1 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human RWPE1 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    		[PMID: 27077446]
    SH-SY5Y IC50
    0.0018 3
    Compound: Docetaxel
    Cytotoxicity against human SH-SY5Y cells assessed as inhibition of cell growth and measured upto 72 hrs by clonogenic assay
    Cytotoxicity against human SH-SY5Y cells assessed as inhibition of cell growth and measured upto 72 hrs by clonogenic assay
    		[PMID: 36126331]
    SK-HEP1 IC50
    0.03 3
    Compound: PC
    Cytotoxicity against human SK-HEP1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human SK-HEP1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 39102454]
    SK-MEL19 GI50
    0.002 3
    Compound: Taxotere
    Antiproliferative activity against human SK-MEL-19 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    Antiproliferative activity against human SK-MEL-19 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    		[PMID: 30802730]
    SK-OV-3 IC50
    0.05 3
    Compound: PC
    Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 39102454]
    SK-OV-3 IC50
    0.75 1
    Compound: Taxotere
    Cytotoxicity against human SKOV3 cells after 72 to 120 hrs by sulforhodamine B assay
    Cytotoxicity against human SKOV3 cells after 72 to 120 hrs by sulforhodamine B assay
    		[PMID: 29517223]
    SW-620 IC50
    0.02 3
    Compound: DTX
    Cytotoxicity against human SW-620 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human SW-620 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 32203786]
    SW-620 IC50
    4.7 1
    Compound: Docetaxel
    Anticancer activity against human SW-620 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Anticancer activity against human SW-620 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 33221063]
    SiHa CC50
    0.22 3
    Compound: Docetaxel
    Cytotoxic activity in human SiHa cells by sulforhodamine B assay
    Cytotoxic activity in human SiHa cells by sulforhodamine B assay
    		[PMID: 29120172]
    SiHa IC50
    0.09 3
    Compound: Docetaxel
    Antiproliferative activity in human SiHa cells by sulforhodamine B assay
    Antiproliferative activity in human SiHa cells by sulforhodamine B assay
    		[PMID: 29120172]
    T84 IC50
    2.7 1
    Compound: Docetaxel
    Anticancer activity against human T84 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Anticancer activity against human T84 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 33221063]
    TERT-RPE1 IC50
    0.0553 3
    Compound: Docetaxel
    Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by real time imaging analysis
    Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by real time imaging analysis
    		[PMID: 33248847]
    TERT-RPE1 IC50
    25 3
    Compound: Docetaxel
    Cytostatic activity against human hTERT-RPE1 cells
    Cytostatic activity against human hTERT-RPE1 cells
    		[PMID: 30738653]
    TERT-RPE1 IC50
    8.2 1
    Compound: DT
    Antiproliferative activity against human RPE-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    Antiproliferative activity against human RPE-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    		[PMID: 38959729]
    U-251 IC50
    0.7 1
    Compound: Docetaxel
    Antiproliferative activity against human U251MG cells after 72 hrs by MTT assay
    Antiproliferative activity against human U251MG cells after 72 hrs by MTT assay
    		[PMID: 30629433]
    Vero CC50
    1.3 3
    Compound: Docetaxel
    Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay
    Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay
    		[PMID: 29120172]
    Vero IC50
    0.13 3
    Compound: Docetaxel
    Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay
    Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay
    		[PMID: 29120172]
    Z-138 IC50
    0.004 3
    Compound: Docetaxel
    Antiproliferative activity against human Z138 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human Z138 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    Z-138 IC50
    0.009 3
    Compound: Docetaxel
    Antiproliferative activity against human Z138 cells
    Antiproliferative activity against human Z138 cells
    		[PMID: 31005446]
    Z-138 IC50
    0.0142 3
    Compound: Docetaxel
    Antiproliferative activity against human Z138 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human Z138 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    Z-138 IC50
    3 3
    Compound: Docetaxel
    Cytostatic activity against human Z138 cells
    Cytostatic activity against human Z138 cells
    		[PMID: 30738653]
    In Vitro

    Docetaxel (RP-56976) and Glufosfamide (GLU) single and combined treatments affect the cells viability in a dose-dependent manner. The IC50 of GLU are 70±4 μM and 86.8±8 μM in PC-3 and LNCaP cells; respectively. While, the IC50 of Docetaxel alone is found to be 3.08±0.4 nM and 1.46±0.2 nM in PC-3 and LNCaP cells; respectively.
    The co-treatment of GLU with Docetaxel is found to synergize the cytotoxicity and the IC50 values are decreased to be 2.7±0.1 nM and 0.75±0.3 nM in PC-3 and LNCaP cells; respectively[1].
    IC50 of NCI-H460 to Docetaxel at 24 h is 116 nM and at 72 h is 30 nM. According to data reported in DTP Data Search, the mean IC50 of NCI-60 cell panel to Docetaxel is 14-34 nM[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Docetaxel Related Antibodies
    In Vivo

    In female mice, the Docetaxel (RP-56976)-induced intestinal apoptosis in the 14-hours after light on (HALO) group is significantly greater than that in the 2-HALO group. Bax expression is significantly elevated by Docetaxel in the 2-HALO group, but not in the 14-HALO group. On the other hand, cleaved Caspase-3 expression is significantly elevated by Docetaxel in the 14-HALO group, but not in the 2-HALO group. The expressions of Wee1 and phosphorylated CKD1 are significantly elevated after dosing of Docetaxel at 14 HALO, but not at 2 HALO. In addition, Docetaxel significantly reduces survivin expression in the 14-HALO group but not in the 2-HALO group. The survivin expression level in the Docetaxel-treated 14-HALO group is significantly smaller than that in the drug-treated 2-HALO group[3].
    Piperine (PIP) is administrated via intravenous bolus at 3.5 mg/kg and via oral administration at 35 mg/kg and 3.5 mg/kg, while Docetaxel (DOX) is intravenously administrated at 7 mg/kg to Sprague-Daley rats. The co-administrations of PIP at 35 mg/kg via oral administration and Docetaxel at 7 mg/kg via intravenous bolus administration in Sprague-Dawley rats. The combination use of PIP and Docetaxel results in a synergic increase of both their in vivo exposure[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Molecular Weight

    807.88

    Formula

    C43H53NO14
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(OC(C)(C)C)N[C@@H](C1=CC=CC=C1)[C@H](C(O[C@@H]2C(C)=C([C@@H](O)C([C@@]3(C)[C@]([C@@](CO4)(OC(C)=O)[C@@]4([H])C[C@@H]3O)([H])[C@@H]5OC(C6=CC=CC=C6)=O)=O)C(C)(C)[C@@]5(O)C2)=O)O
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, protect from light

    *In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (123.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Ethanol : 50 mg/mL (61.89 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.2378 mL 6.1890 mL 12.3781 mL
    5 mM 0.2476 mL 1.2378 mL 2.4756 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% EtOH    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 5 mg/mL (6.19 mM); Clear solution

      This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% EtOH    90% Corn Oil

      Solubility: ≥ 5 mg/mL (6.19 mM); Clear solution

      This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.94%

    SDS (558 KB)

    COA (260 KB) HNMR (311 KB) LCMS (89 KB)

    Handling Instructions (2659 KB)
    References
    Cell Assay
    [1]

    Single-drug concentration-response curves are assessed. Seeding is done at a density of 2,000 cells/well for PC-3 and LNCaP, in 96-well plates. Cells are treated with each single drug and their combination for 72 h at different drug concentrations. Docetaxel is used at concentrations of 0.1-1,000 nM. GLU is used at concentrations of 0.1-300 µm. Cytotoxicity is assessed at the end of drug exposure using SRB assay. Following 72 h exposure the cells are fixed with 10% trichloroacetic acid (150 µL) for 1 h at 4°C. Then, cells are stained for 10 min at room temperature with 0.4% SRB dissolved in 1% acetic acid. The plates are then air dried for 24 h and the dye is made soluble with 150 µL Tris (10 mM, PH 7.4) for 5 min on a shaker at 1,600 rpm. Absorbance is then measured at 545 nM using microplate reader. Results are expressed as the relative percentage of absorbance compared to control[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [3][4]

    Mice[3]
    Five-week-old male Balb/c mice are used. Docetaxel (0, 10, 20, 30, 40, 60, and 80 mg/kg per week) is given once a week for 3 weeks for mice. Because more than 30 mg/kg per week of Docetaxel causes body weight loss in mice, 20 mg/kg per week of Docetaxel is judged to be the maximum nontoxic dose. Docetaxel (20 mg/kg per week) is given to mice once a week for 3 weeks at one of the following different points (2, 10, 14, or 22 HALO). Seventy-two hours after the final dosing of the agent, the intestinal mucosa of the small intestine (proximal 8 cm) is removed, fixed in 20 N Mildform solution (containing 8% formaldehyde in a buffered solution), and embedded in paraffin blocks, and sections of 5 μm are put on glass slides. Apoptosis is detected using the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) method, using the Apop Tag Peroxidase In Situ Apoptosis Detection Kit.
    Rats[4]
    Male Sprague-Dawley rats with body weight between 230-250 g and age between 6-7 weeks are used. About 25 SD rats are divided into five groups receiving Docetaxel (7 mg/kg, i.v.), PIP (35 mg/kg, p.o.) and their combined administration (DOX+PIP) as well as PIP (3.5 mg/kg, p.o.) and PIP (3.5 mg/kg, i.v.). A day before the drug administrations, the rats are anesthetized. Right jugular vein is cannulated with a polyethylene tubing (0.5 mm ID, 1 mm) for blood collection.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    Ethanol / DMSO 1 mM 1.2378 mL 6.1890 mL 12.3781 mL 30.9452 mL
    5 mM 0.2476 mL 1.2378 mL 2.4756 mL 6.1890 mL
    10 mM 0.1238 mL 0.6189 mL 1.2378 mL 3.0945 mL
    15 mM 0.0825 mL 0.4126 mL 0.8252 mL 2.0630 mL
    20 mM 0.0619 mL 0.3095 mL 0.6189 mL 1.5473 mL
    25 mM 0.0495 mL 0.2476 mL 0.4951 mL 1.2378 mL
    30 mM 0.0413 mL 0.2063 mL 0.4126 mL 1.0315 mL
    40 mM 0.0309 mL 0.1547 mL 0.3095 mL 0.7736 mL
    50 mM 0.0248 mL 0.1238 mL 0.2476 mL 0.6189 mL
    60 mM 0.0206 mL 0.1032 mL 0.2063 mL 0.5158 mL
    DMSO 80 mM 0.0155 mL 0.0774 mL 0.1547 mL 0.3868 mL
    100 mM 0.0124 mL 0.0619 mL 0.1238 mL 0.3095 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Docetaxel Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Docetaxel114977-28-5RP-56976RP56976RP 56976Microtubule/TubulinApoptosisEndogenous MetaboliteInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Docetaxel
    Cat. No.:
    HY-B0011
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (558 KB) Français - FR (558 KB) Deutsch - DE (558 KB) Norwegian - NO (558 KB) Español - ES (558 KB) Swedish - SV (558 KB) Italian - IT (558 KB) Korean - KR (558 KB) Portuguese - PT (558 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.